Regional Footprint

Explore Markets

Inpharmus has an established presence in each of the territories shown on this interactive map.

Click on a region to learn more about our regional operations and the local market opportunities we can help you access..

When you’re ready, click the button below to find out about our product case studies.

Click on Each Region to Discover More
RUSSIA
KAZAKHSTAN
KYRGZYSTAN
GCC
Tunisia
Algeria
Turkey
IRAQ
JORDAN
Macedonia
Albania

Our Partners

We collaborate with over 10 international biopharma leaders and have been recognized for excellence in market access and commercialization. Our expertise allows us to navigate complex regulatory environments and execute successful market strategies with efficiency and precision

Get in Touch

HEADQUARTERS: Esentepe Mh. Büyükdere Cd. Kanyon Ofis Bloğu No: 185 Kat: 14 34394 Levent-Şişli İSTANBUL/TÜRKİYE

Toll FREE: +90 212 386 31 30, +90 212 386 31 61

Email: info@inpharmus.com

Dubai Branch: Dubai Science Park – North Tower 11th Floor Al Barsha South, Dubai, United Arab Emirates

Toll FREE: +971 4835 7899

Moscow Branch: Solovjinaya roshcha bld. no3, fl. 40, Kurkino District, 125466, Moscow Russia
‍Toll FREE: +7 495 150 75 06

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

INPHARMUS İLAÇ SANAYİ TİCARET ANONİM ŞİRKETİ

Follow Us
Quick Links
HomeAbout UsTherapeutic areasContact Us
Links
Privacy PolicyCookie PolicyTerms of Use

© Copyright 2025 Inpharmus — All Rights Reserved.

russia: a growing market for rare disease therapies

Russia’s €21 billion pharma market is heavily influenced by state procurement, particularly in high-need areas like oncology and rare diseases. These diseases account for ~25% of the total market size, making them a significant focus area.

In 2023, the orphan drug market grew 10% to €2.4 billion, driven by the increasing reimbursement of rare diseases through special funds established across the region. These funds reflect a growing commitment to addressing unmet medical needs.

Inpharmus plays a central role in this space, directly commercialising four rare disease products under its full operational control. This end-to-end approach ensures seamless integration of global strategies with local market needs, supported by high-performance standards and streamlined alliance management processes.

turkey: inpharmus’ core market and strategic hub

Turkey is Inpharmus’ primary market, showcasing its expertise in navigating complex healthcare systems. The $890 million oncology and haematology market, with an 11% CAGR over the past five years, is driven by expanding reimbursement opportunities and a $200 million named patient access channel offering near EU-US level pricing.

The rare diseases market, valued at $650 million with an 11% CAGR, presents additional opportunities through a $250 million named patient access channel.

With over a decade of experience, Inpharmus ensures seamless execution of global strategies, managing reimbursement approvals and compliance. Turkey’s status as a leader in immunology diagnosis and rare disease therapies underscores Inpharmus’ pivotal role in driving healthcare innovation​.

the gcc: a high-growth region for lifesaving therapies

The Gulf Cooperation Council (GCC) countries represent a rapidly expanding pharmaceutical market, particularly in oncology and rare diseases. The oncology and haematology market, valued at $800 million, has achieved a robust 12% CAGR over the past five years.

Similarly, the rare diseases market, valued at $550 million, mirrors this growth trajectory with a 12% CAGR. Both sectors benefit from clear regulations for named patient access, enabling fast registration and reimbursement timelines with near EU-US level pricing.

The GCC is characterised by a high prevalence of immunodeficiency, neurodegenerative, and inherited metabolic disorders, largely attributed to the region's high rate of consanguineous marriages. This creates a pressing need for life-saving therapies, particularly in rare and severe conditions.

The GCC is characterised by a high prevalence of immunodeficiency, neurodegenerative, and inherited metabolic disorders, largely attributed to the region's high rate of consanguineous marriages. This creates a pressing need for life-saving therapies, particularly in rare and severe conditions.

algeria: a fast-growing market with strong oncology demand

Algeria is the second-largest pharmaceutical market in Africa, valued at $4 billion, with a 17% compound annual growth rate (CAGR) over the past decade. The country provides free universal healthcare to its 44 million citizens, driving strong demand for innovative treatments.

The hospital sector accounts for 33% of the market, while oncology represents 55%, reflecting Algeria’s high need for specialised care. In 2024, the hospital segment is estimated at $1.4 billion, with oncology at $780 million, experiencing 55% growth over four years.

Algeria’s pharmaceutical landscape is shaped by government-controlled procurement. The Pharmacie Centrale des Hôpitaux (PCH) is the sole importer of medicines that are not yet registered, centralising drug purchases. The Ministry of the Pharmaceutical Industry (MOPI), established in 2020, has significantly reduced drug registration timelines from five years to as little as six months for life-saving treatments.

Additionally, Algeria has implemented Named Patient Access (NPA), allowing temporary authorisation for medicines treating serious diseases with no alternatives before obtaining full market approval.

Additionally, Algeria has implemented Named Patient Access (NPA), allowing temporary authorisation for medicines treating serious diseases with no alternatives before obtaining full market approval.

iraq: a growing market with a centralised procurement system

Iraq’s pharmaceutical market has demonstrated high single-digit growth over the past decade and is now estimated at $5.2 billion. The country’s healthcare system is heavily reliant on government procurement, with strict regulatory pathways governing access to medicines.

KIMADIA, the centralised government tender management and purchasing body, is responsible for all oncology, haematology, and rare disease treatments, making it the primary gateway for pharmaceutical companies looking to enter the market.
The National Committee for Drugs Selection (NBDS) oversees the inclusion of medicines and vaccines in both the national essential medicines list (EML) and the comprehensive medicines list. Once a product is listed on the EML, it must undergo Good Manufacturing Practice (GMP) certification and full registration, ensuring compliance with national regulatory standards.

For companies seeking expedited access, Iraq offers a fast-track evaluation process that reduces the registration timeline to nine months, allowing for quicker patient access to critical treatments.

For companies seeking expedited access, Iraq offers a fast-track evaluation process that reduces the registration timeline to nine months, allowing for quicker patient access to critical treatments.

kazakhstan: an expanding market for rare disease therapies

Kazakhstan is emerging as a key player in Central Asia’s healthcare transformation, with increasing focus on innovation, equity, and access. Rare diseases, once underdiagnosed and overlooked, are now being prioritized through dedicated government programs, improved diagnostic infrastructure, and evolving reimbursement policies. This shift reflects a national commitment to elevate healthcare standards and close treatment gaps for underserved patient groups.


Inpharmus is actively contributing to this evolution by introducing rare disease therapies that are aligned with Kazakhstan’s local clinical needs and regulatory environment. With full operational control, the company ensures seamless execution from market entry to long-term product support—leveraging strategic alliances and region-specific expertise.By combining global excellence with local focus, Inpharmus is helping shape a more inclusive rare disease ecosystem in Kazakhstan, one that not only provides access to innovative therapies but also foster collaboration, sustainability, and long-term impact for the entire healthcare community.

Kyrgyzstan: A Growing Hub For Rare Disease Care

Kyrgyzstan’s evolving healthcare landscape is becoming increasingly receptive to innovative therapies, particularly in the rare and orphan disease space. While the country’s pharmaceutical market is still in its developmental phase, there is a visible shift towards recognizing and addressing high-priority unmet medical needs. Rising public awareness, support from international partners, and government-led health initiatives are collectively driving improvements in diagnosis, treatment access, and reimbursement frameworks.

As part of this transformation, Inpharmus is strategically expanding its footprint in Kyrgyzstan by introducing globally approved therapies adapted to local healthcare requirements. With end-to-end operational oversight, Inpharmus manages everything from regulatory approvals and supply chain management to physician engagement and patient support programs.

The company’s model is rooted in agile execution and deep regional understanding, enabling it to align global standards with local realities. By strengthening collaborations with local stakeholders and ensuring long-term availability of therapies, Inpharmus is helping to build a sustainable ecosystem for rare disease care—one that brings meaningful change to underserved patient communities across the region.

Jordan: Rising Healthcare Needs in Jordan

Jordan is witnessing a steady rise in healthcare demand, fueled by the growing burden of lifestyle-related diseases and a gradual shift in public awareness toward mental health. Non-communicable diseases such as diabetes, hypertension, and heart conditions are increasingly common due to urban lifestyles, dietary changes, and reduced physical activity. These long-term health conditions require ongoing medical support and are driving demand for more structured and accessible healthcare systems.

In parallel, there’s a rising awareness around mental health issues in Jordan, particularly among the youth and urban population. Anxiety, depression, and stress-related concerns are becoming more openly discussed, leading to increased interest in counseling, therapy, and community-based mental health initiatives.

The healthcare system is adapting to this evolving landscape with more focus on preventive care, early diagnosis, and personalized treatment options. As people become more informed about their health, both physical and mental, Jordan’s medical sector is being pushed to offer broader services, better access, and modern therapeutic solutions.

Albania: The Growing Demand forHealthcare

Albania is experiencing a growing demand for healthcare services, driven by an increase in chronic illnesses and mental health challenges. Chronic diseases like diabetes, hypertension, and cardiovascular issues are becoming more prevalent, creating an urgent need for long-term care, monitoring, and lifestyle management. These conditions require continuous medical attention and have placed pressure on Albania's healthcare infrastructure.

Mental health is another critical area where demand is rising. With the increasing awareness around mental health, more individuals are seeking therapy and support for conditions like depression, anxiety, and stress. This shift indicates a growing recognition of the importance of mental well-being in overall health.

Additionally, lifestyle-related diseases, such as obesity, respiratory problems, and other non-communicable diseases, are contributing to the rising healthcare needs. In response to these trends, there is a greater emphasis on preventative measures, early detection, and a more holistic approach to healthcare that addresses both physical and mental health concerns. The growing healthcare demand in Albania reflects a need for more specialized services and an integrated approach to care for chronic and mental health issues.

North Macedonia: Transforming the Future of Rare Disease Treatment Access

In North Macedonia, the treatment and management of rare diseases remain a challenge for both patients and healthcare providers. Although there has been some progress in recent years, rare disease patients still face significant barriers to care. One of the main issues is the limited awareness and knowledge of these conditions among healthcare professionals, which can delay diagnosis and treatment. Additionally, there is a shortage of specialized healthcare facilities and trained medical staff to handle these complex cases.

The government has initiated some positive steps, such as creating national registries for rare diseases and participating in international collaborations to improve access to treatment. However, due to limited funding and resources, many patients struggle to access the treatments they need. High treatment costs and the lack of local specialists force many families to seek medical assistance abroad, often resulting in financial strain.

Although progress is slow, there is growing recognition of the need to address these challenges, and efforts are being made to improve the healthcare system for those suffering from rare diseases in North Macedonia.

Tunisia: The Growing Demand for 
Healthcare in Tunisia

In Tunisia, there is a noticeable rise in the demand for healthcare services, largely driven by the increasing prevalence of chronic conditions and mental health concerns. Chronic diseases like diabetes, hypertension, and heart disease are becoming more common, leading to a higher need for ongoing medical care, medication, and lifestyle management programs.

At the same time, mental health is emerging as a key area of focus, with more individuals seeking therapy for stress, anxiety, and depression. As mental well-being becomes a priority, there is a growing need for accessible mental health services.

Furthermore, lifestyle diseases such as obesity and respiratory conditions are on the rise, further contributing to the growing demand for healthcare services in the country. In response, there is a stronger focus on prevention and early intervention, alongside specialized treatment options for chronic and lifestyle-related health issues. This trend highlights a shift towards comprehensive healthcare that addresses both physical and mental health needs.